Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
HCM is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of HCM shares has decreased $0.31 since the market last closed. This is a 2.08% ...
Disclaimer: these videos were produced in 2011, but we have had positive feedback in relation to them in 2016 so we hope you find them useful! The following links will take you videos of individual ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results